CY503 for the Treatment of Malignant Melanoma Stage IV After Failure of Prior Therapy
Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
The trial is designed as a phase II evaluation of the effect of CY-503 on progression free
survival (PFS) in patients with stage IV malignant melanoma after failure of prior therapy.
The aim of the study is at least a rate of 25% (PFS >/= 3 months).